Skip to search formSkip to main contentSkip to account menu

vidofludimus

Known as: 2-(3-fluoro-3'-methoxybiphenyl-4-carbamoyl)cyclopent-1-enecarboxylic acid, 4SC-101 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Biphenyl CompoundsDicarboxylic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
Background and Objective Vidofludimus is a potent and selective inhibitor of human mitochondrial enzyme dihydroorotate… 
2020
2020
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
2020
2020
Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological… 
2019
2019
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
The dihydroorotate dehydrogenase (DHODH) inhibitors leflunomide and teriflunomide are immunomodulatory agents approved to treat… 
Highly Cited
2013
Highly Cited
2013
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
2012
2012
Vidofludimus Inhibits Colonic Interleukin-17 and Improves Hapten-Induced Colitis in Rats by a Unique Dual Mode of Action
Vidofludimus (Vido) is a novel oral immunomodulatory drug that inhibits dihydro-orotate dehydrogenase and lymphocyte… 
2012
2012
Immunosuppression With 4SC-101, a Novel Inhibitor of Dihydroorotate Dehydrogenase, in a Rat Model of Renal Transplantation
Background 4SC-101 is a novel dihydroorotate dehydrogenase inhibitor and a blocker of interleukin (IL)-17 secretion with… 
Highly Cited
2010
Highly Cited
2010
4SC‐101, a novel immunosuppressive drug, inhibits IL‐17 and attenuates colitis in two murine models of inflammatory bowel disease†
Background: Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for… 
Highly Cited
2010
Highly Cited
2010
4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better… 
2010
2010
Immunopathology and Infectious Diseases 4 SC-101 , A Novel Small Molecule Dihydroorotate Dehydrogenase Inhibitor , Suppresses Systemic Lupus Erythematosus in MRL-( Fas ) lpr Mice
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License